Novel therapeutics for melanoma

References

• Cancer Facts and Figures. In: American Cancer Society. American Cancer Society, GA, USA (2008).
   Google Scholar
• Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol.19, 3622–3634 (2001).
   PubMed Web of Science ®Google Scholar
• Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol.17, 2745–2751 (1999).
   PubMed Web of Science ®Google Scholar
• Mays SR, Nelson BR. Current therapy of cutaneous melanoma. Cutis63, 293–298 (1999).
   PubMedGoogle Scholar
• Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol.18, 158–166 (2000).
   PubMed Web of Science ®Google Scholar
• Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J. Exp. Clin. Cancer Res.19, 21–34 (2000).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17, 2105–2116 (1999).
   PubMed Web of Science ®Google Scholar
• Grob JJ, Dreno B, de la Salmoniere P et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet351, 1905–1910 (1998).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon α-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol.18, 2444–2458 (2000).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol.14, 7–17 (1996).
   PubMed Web of Science ®Google Scholar
• Atkins MB, O’Boyle KR, Sosman JA et al. Multiinstitutional Phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J. Clin. Oncol.12, 1553–1560 (1994).
   PubMed Web of Science ®Google Scholar
• Legha SS, Ring S, Eton O et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon α, and interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol.16, 1752–1759 (1998).
   PubMed Web of Science ®Google Scholar
• McDermott DF, Mier JW, Lawrence DP et al. A Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon α-2B in patients with metastatic melanoma. Clin. Cancer Res.6, 2201–2208 (2000).
   PubMed Web of Science ®Google Scholar
• Richards JM, Gale D, Mehta N, Lestingi T. Combination of chemotherapy with interleukin-2 and interferon α for the treatment of metastatic melanoma. J. Clin. Oncol.17, 651–657 (1999).
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Boasberg PD, Piro L et al. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin. Cancer Res.8, 2775–2781 (2002).
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Gammon G, Boasberg PD et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J. Clin. Oncol.17, 2752–2761 (1999).
   PubMed Web of Science ®Google Scholar
• Eton O, Legha SS, Bedikian AY et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial. J. Clin. Oncol.20, 2045–2052 (2002).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hsu J, Lee S et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon α-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol.26, 5748–5754 (2008).
   PubMed Web of Science ®Google Scholar
• Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J. Clin. Oncol.25, 5426–5434 (2007).
   PubMed Web of Science ®Google Scholar
• Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr. Opin. Oncol.20, 183–189 (2008).
   PubMed Web of Science ®Google Scholar
• Shields JM, Thomas NE, Cregger M et al. Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res.67, 1502–1512 (2007).
   PubMed Web of Science ®Google Scholar
• Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res.62, 6997–7000 (2002).
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417, 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Meier F, Schittek B, Busch S et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front. Biosci.10, 2986–3001 (2005).
   PubMed Web of Science ®Google Scholar
• Smalley KS, Haass NK, Brafford PA et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther.5, 1136–1144 (2006).
   PubMed Web of Science ®Google Scholar
• Kasper B, D’Hondt V, Vereecken P, Awada A. Novel treatment strategies for malignant melanoma: a new beginning? Crit. Rev. Oncol. Hematol.62, 16–22 (2007).
   PubMed Web of Science ®Google Scholar
• Poynter JN, Elder JT, Fullen DR et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res.16, 267–273 (2006).
   PubMed Web of Science ®Google Scholar
• Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43–9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol.407, 597–612 (2006).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer95, 581–586 (2006).
   PubMed Web of Science ®Google Scholar
• Amaravadi RK, Schuchter L, McDermott DF et al. Updated results of a randomized Phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J. Clin. Oncol.25, 8527 (2007).
   Google Scholar
• Flaherty KT, Schiller J, Schuchter LM et al. A Phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res.14, 4836–4842 (2008).
   PubMed Web of Science ®Google Scholar
• Agarwala S, Keilholz U, Hogg C et al. Randomized Phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J. Clin. Oncol.25, (2007) (Abstract 8510).
   PubMed Web of Science ®Google Scholar
• McDermott, Sosman J, Hodi FS et al. Randomized Phase II study of dacarbazine with and without sorafenib in patients with advanced melanoma. J. Clin. Oncol.25, (2007) (Abstract 8511).
   Google Scholar
• Sarker D, Molife R, Evans TR et al. A Phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin. Cancer Res.14, 2075–2081 (2008).
   PubMed Web of Science ®Google Scholar
• Fruehauf JP, Lutzky J, McDermott DF et al. Axitinib (AG-013736) in patients with metastatic melanoma: a Phase II study. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 9006).
   Web of Science ®Google Scholar
• Chan KR, Laudadio M, Mastrangelo M et al. A pilot study using sunitinib malate as therapy in patients with stage IV uveal melanoma. J. Clin. Oncol.26, (2008) (Abstract 9047).
   Google Scholar
• Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol.19, 577–583 (2001).
   PubMed Web of Science ®Google Scholar
• Perez DG, Suman VJ, Fitch TR et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer115, 119–127 (2009).
   PubMed Web of Science ®Google Scholar
• Peterson AC, Swiger S, Stadler WM et al. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin. Cancer Res.10, 4048–4054 (2004).
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Griffith DJ, Druker BJ et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood96, 925–932 (2000).
   PubMed Web of Science ®Google Scholar
• Ugurel S, Hildenbrand R, Zimpfer A et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer92, 1398–1405 (2005).
   PubMed Web of Science ®Google Scholar
• Wyman K, Atkins MB, Prieto V et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer106, 2005–2011 (2006).
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol.24, 4340–4346 (2006).
   PubMed Web of Science ®Google Scholar
• Hodi FS, Friedlander P, Corless CL et al. Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol.26, 2046–2051 (2008).
   PubMed Web of Science ®Google Scholar
• Fecher LA, Amaravadi K, Flaherty KT et al. Phase I/II trial of imatinib and temozolomide in advanced unresectable melanoma. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 9059).
   Google Scholar
• Tsai J, Zhang J, Bremer R, et al. Development of a novel inhibitor of oncogenic B-Raf. Proc. Amer. Assoc. Cancer Res.47 (2006) (Abstract 4855).
   Google Scholar
• Sala E, Mologni L, Truffa S et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol. Cancer Res.6, 751–759 (2008).
   PubMed Web of Science ®Google Scholar
• Amiri P, Aikawa M, Dove J et al. CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations. Proc. Amer. Assoc. Cancer Res.47, (2006) (Abstract 4855).
   Google Scholar
• Adjei AA, Cohen RB, Franklin W et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol.26, 2139–2146 (2008).
   PubMed Web of Science ®Google Scholar
• Dummer R, Robert C, Chapman PB et al. AZD6244 (ARRY-142886) vs. temozolomide in patients with advanced melanoma: an open label, randomized, multicenter, Phase II study. J. Clin. Oncol.26, (2008) (Abstract 9033).
   Web of Science ®Google Scholar
• Lorusso P, Krishnamurthi S, Rinehart JR et al. A Phase I–II clinical study of a second generation oral MEK inhibitor, PD 0325901, in patients with advanced cancer. J. Clin. Oncol.23(Suppl.), (2005) (Abstract 3011).
   Google Scholar
• Stahl JM, Sharma A, Cheung M et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res.64, 7002–7010 (2004).
   PubMed Web of Science ®Google Scholar
• Rao RD, Windschitl H, Allred JB et al. Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. J. Clin. Oncol.24(Suppl.), 8043 (2007).
   Google Scholar
• Rao RD, Alldred J, Windschitl HE et al. Results of NCCTG Phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma. J. Clin. Oncol.25(Suppl.), 8530 (2007).
   Web of Science ®Google Scholar
• Kirkwood JM, Manola J, Ibrahim J et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res.10, 1670–1677 (2004).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol.26, 5233–5239 (2008).
   PubMed Web of Science ®Google Scholar
• Faries MB, Morton DL. Therapeutic vaccines for melanoma: current status. BioDrugs19, 247–260 (2005).
   PubMedGoogle Scholar
• Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Rev. Vaccines3(5), 521–527 (2004).
   PubMedGoogle Scholar
• Mitchell MS, Abrams J, Thompson JA et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon α-2b compared with high-dose interferon α-2b for resected stage III cutaneous melanoma. J. Clin. Oncol.25, 2078–2085 (2007).
   PubMed Web of Science ®Google Scholar
• Demir G, Klein HO, Tuzuner N. Low dose daily rhGM-CSF application activates monocytes and dendritic cells in vivo. Leuk. Res.27, 1105–1108 (2003).
   PubMedGoogle Scholar
• Vuylsteke RJ, Molenkamp BG, Gietema HA et al. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res.64, 8456–8460 (2004).
   PubMed Web of Science ®Google Scholar
• Spitler LE, Grossbard ML, Ernstoff MS et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte–macrophage colony-stimulating factor. J. Clin. Oncol.18, 1614–1621 (2000).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Lee S, Moschos SJ et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte–monocyte colony-stimulating factor and/or IFN-α2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin. Cancer Res.15, 1443–1451 (2009).
   PubMed Web of Science ®Google Scholar
• Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol.19, 565–594 (2001).
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med.182, 459–465 (1995).
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol.23, 6043–6053 (2005).
   PubMed Web of Science ®Google Scholar
• Kadowaki N, Ho S, Antonenko S et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med.194, 863–869 (2001).
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov.5, 471–484 (2006).
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science271, 1734–1736 (1996).
   PubMed Web of Science ®Google Scholar
• Ribas A, Camacho LH, Lopez-Berestein G et al. Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol.23, 8968–8977 (2005).
   PubMed Web of Science ®Google Scholar
• Gomez-Navarro J, Sharma A, Bozon V et al. Dose and schedule selection for the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in patients (pts) with metastatic melanoma. J. Clin. Oncol.24(Suppl.), (2006) (Abstract 8032).
   Google Scholar
• Ribas A, Antonia S, Sosman J et al. Results of a Phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. J. Clin. Oncol.25(Suppl.), (2007) (Abstract 3000).
   Google Scholar
• Ribas A, Hauschild A, Kefford R et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J. Clin. Oncol.26, LBA 9011 (2008).
   Google Scholar
• Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA100, 8372–8377 (2003).
   PubMed Web of Science ®Google Scholar
• Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol.12, 1005–1016 (2005).
   PubMed Web of Science ®Google Scholar
• Weber JS, Berman D, Segel J et al. Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 9010).
   Web of Science ®Google Scholar
• Wolchok JD, Ibrahim R, DePril V et al. Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 3020).
   PubMedGoogle Scholar
• Brahmer JR, Topalian S, Wollner I et al. Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J. Clin. Oncol.26(Suppl.), 3006 (2008).
   PubMedGoogle Scholar
• Sznol M, Hodi FS, Margolin K. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J. Clin. Oncol.26(Suppl.), (2008) (Abstract 3007).
   Google Scholar
• Vonderheide RH, Flaherty K, Khalil M et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol.24(Suppl.), (2006).
   PubMedGoogle Scholar
• Pashenkov M, Goess G, Wagner C et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol.24, 5716–5724 (2006).
   PubMed Web of Science ®Google Scholar
• Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene22, 3138–3151 (2003).
   PubMed Web of Science ®Google Scholar
• Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev.12, 193–213 (2002).
   PubMedGoogle Scholar
• Jansen B, Wacheck V, Heere-Ress E et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet356, 1728–1733 (2000).
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol.24, 4738–4745 (2006).
   PubMed Web of Science ®Google Scholar
• Pavlick AC, Escalon J, Madden K et al. A Phase I/II study to determine the feasibility and efficacy of the triple combination of oblimersen (OBL), abraxane (ABX), and temozolomide (TMZ) in metastatic melanoma and normal LDH. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 9027).
   PubMedGoogle Scholar
• Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature283, 593–596 (1980).
   PubMed Web of Science ®Google Scholar
• Staibano S, Pepe S, Lo Muzio L et al. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum. Pathol.36, 724–731 (2005).
   PubMed Web of Science ®Google Scholar
• Plummer ER, Middleton M, Wilson R et al. First in human Phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumor. J. Clin. Oncol.23, (2005) (Abstract 208S).
   Google Scholar
• Plummer ER, Lorigan P, Evans J et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J. Clin. Oncol.24(Suppl.), (2006) (Abstract 456s).
   Google Scholar
• Tse KF, Jeffers M, Pollack VA et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin. Cancer Res.12, 1373–1382 (2006).
   PubMed Web of Science ®Google Scholar
• Hwu P, Sznol M, Kluger H et al. A Phase I/II study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 9029).
   Google Scholar
• Trikha M, Zhou Z, Nemeth JA et al. CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer110, 326–335 (2004).
   PubMed Web of Science ®Google Scholar
• Jayson GC, Mullamitha S, Ton C et al. Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to v integrins, in patients with solid tumors. J. Clin. Oncol.23(Suppl.), (2005) (Abstract 3113)
   Google Scholar